This public procurement record has 4 releases in its history.

Award

12 Nov 2026 at 10:34

Tender

19 Jun 2026 at 10:52

Planning

17 Jun 2026 at 12:54

Planning

22 May 2026 at 19:31

Summary of the contracting process

The UK Health Security Agency is buying measles, mumps and rubella (MMR) vaccine for use in the national immunisation programme. This is a supply contract for the vaccine, rather than a wider vaccination or clinical service. Deliveries are for the United Kingdom. The procurement was not divided into lots, so the requirement was awarded as a single package. The buyer is the Secretary of State for Health and Social Care, acting through the UK Health Security Agency, which manages the national programme and its vaccine supply. The product must protect against all three diseases and support the programme’s immunisation needs. The requirement concerns vaccine supply and delivery; the procurement does not describe associated administration services or other products.

The procurement has been awarded to Merck Sharp & Dohme (UK) Ltd following an open procedure, with one bid recorded. The award date was 29 October 2026. The contract is scheduled to run from 1 May 2027 to 30 September 2029, a fixed term of 29 months. The contract value is withheld to protect the supplier’s legitimate commercial interests, so no awarded amount is published. Bids were assessed against the vaccine specification, benchmark and vaccine prices, additional costs and savings, storage costs, risk to programme delivery and social value. Economic and technical selection requirements were covered in the procurement questionnaire. The award is pending; contract signature was scheduled for 27 November 2026. Standard payment terms are 30 days.

This award shows continuing public demand for MMR vaccine supply to the UK’s national immunisation programme. A credible competitor when this requirement next reaches the market would need to be a UK-licensed supplier able to provide a vaccine protecting against measles, mumps and rubella, and to demonstrate that its product meets the buyer’s specification. The buyer’s assessment also indicates the importance of dependable delivery and managing risks to programme supply, alongside competitive vaccine pricing, benchmark pricing, additional costs and savings, and storage costs. Suppliers should be able to evidence technical and economic capacity through the procurement questionnaire and address social value. The requirement was awarded as one package, so competing suppliers would need capability to serve the national requirement rather than only a separately awarded lot. One bid was received in this competition.

How relevant is this notice?

Notice Information

Notice Title

Measles, Mumps and Rubella (MMR) vaccine (2027)

Notice Description

A contract for the supply of a vaccine to protect against measles, mumps and rubella, to be used as part of the national immunisation programme. Deliveries are over a fixed term of 29 months, starting May 2027 through to 30 September 2029 The awarding of lots was not appropriate for this procurement. Value - The contract value is withheld from publication pursuant to regulation 94(2)(b) of the Procurement Act 2023, so as not to prejudice the legitimate commercial interest of the supplier.

Planning Information

The UK Health Security Agency sent a short pre-market engagement questionnaire to known UK licensed suppliers of measles, mumps and rubella vaccine. Insights collected primarily focused on product, volumes and supply chain to better understand the current market landscape.

Notice Details

Publication & Lifecycle

Open Contracting ID
ocds-h6vhtk-06a254
Publication Source
Find A Tender Service
Latest Notice
https://www.find-tender.service.gov.uk/Notice/107443-2026
Current Stage
Award
All Stages
Planning, Tender, Award

Procurement Classification

Notice Type
UK6 - Contract Award Notice
Procurement Type
Standard
Procurement Category
Goods
Procurement Method
Open
Procurement Method Details
Open procedure
Tender Suitability
Not specified
Awardee Scale
Large

Common Procurement Vocabulary (CPV)

CPV Divisions

33 - Medical equipments, pharmaceuticals and personal care products


CPV Codes

33651600 - Vaccines

33651640 - Measles-mumps-rubella vaccines

Notice Value(s)

Tender Value
Not specified
Lots Value
Not specified
Awards Value
Not specified
Contracts Value
Not specified

Notice Dates

Publication Date
12 Nov 20264 days ago
Submission Deadline
24 Jul 2026Expired
Future Notice Date
19 Jun 2026Expired
Award Date
29 Oct 20262 weeks ago
Contract Period
1 May 2027 - 30 Sep 2029 2-3 years
Recurrence
2028-04-03

Notice Status

Tender Status
Complete
Lots Status
Complete
Awards Status
Pending
Contracts Status
Not Specified

Buyer & Supplier

Contracting Authority (Buyer)

Main Buyer
UK Health Security Agency
Contact Name
Available with D3 Tenders Premium →
Contact Email
Available with D3 Tenders Premium →
Contact Phone
Available with D3 Tenders Premium →

Buyer Location

Locality
LONDON
Postcode
E14 4PU
Postcode Area
East London
Country
England

Major Region (ITL 1)
TLI London
Basic Region (ITL 2)
TLI4 Inner London - East
Small Region (ITL 3)
TLI42 Tower Hamlets
Delivery Location
Not specified

Local Authority
Tower Hamlets
Electoral Ward
Canary Wharf
Westminster Constituency
Poplar and Limehouse

Supplier Information

Number of Suppliers
1
Supplier Name

Merck Sharp & Dohme UK Ltd

Further Information

Notice Documents

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

JSON Markdown

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.

Loading OCDS record...